CompletedPhase 3NCT02020369
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- rEVO Biologics
- Principal Investigator
- Jean Francois Schved, MDSaint Eloi Hospital
- Intervention
- Coagulation Factor VIIa (Recombinant)(biological)
- Enrollment
- 27 enrolled
- Eligibility
- 12-75 years · MALE
- Timeline
- 2014 – 2015
Study locations (17)
- Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
- Republican Research Center for Radiation Medicine and Human Ecology, Homyel, Belarus
- Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria
- LTD HEMA, Tbilisi, Georgia
- Chaim Sheba Medical Center, Tel-hashomer hospital, Ramat Gan, Israel
- Institute of Hematology and Transfusion Medicine, Warsaw, Poland
- Sandor SRL, Bucharest, Romania
- Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russia
- Hematology Research Center, Moscow, Russia
- City Outpatient Clinic #37, Saint Petersburg, Russia
- Kyiv City Clinical Hospital #9, Kyiv, Ukraine
- +2 more locations on ClinicalTrials.gov
Collaborators
Laboratoire français de Fractionnement et de Biotechnologies
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02020369 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.